OPTH
****Sponsored by TD Media, LLC
Optimi Health Corp. manufactures finished-dose psilocybin and MDMA capsules at a Health Canada Drug Establishment-licensed facility in British Columbia, and supplies them to authorized psychiatrists in Australia under the TGA Authorized Prescriber Scheme
OPTH Rides Historic Psychedelic Policy Wave as US Executive Order Fast-Tracks Regulatory Path
This Revenue-Generator Scales toward 100 Clinics as Psilocybin and MDMA Market Access Expands Across Four Countries
Check Out the Investor Presentation HERE
____________________________
Hello Everyone,
The market just opened and we want you to quickly turn your attention to Optimi Health Corp. (NASDAQ: OPTH) is sitting at the center of one of the most explosive regulatory tailwinds in biotech right now, and this Canadian company is already generating real revenue while the psychedelic medicine space heats up around it. Optimi isn't some early-stage dreamer waiting on a trial readout — it's a vertically integrated, cGMP-certified manufacturer running a 20,000 square foot facility that's been shipping actual product since Q2 2024. The company makes naturally-derived psilocybin capsules and MDMA HCl capsules, and it's one of the only players in the world supplying both to authorized prescribers, giving it a natural-API edge in a field where most competitors are stuck with synthetic formulations. As of Q1 2026, Optimi has shipped roughly 5,000 doses globally, with MDMA export volumes scaling from just 160 doses per shipment up to 1,000, and its Australian prescriber network sitting at 26 clinics with a target of 100 by early 2027.
And the timing could not be better. Just this year, a US Executive Order dropped in April fast-tracking psychedelic research and regulatory review, complete with priority vouchers, Right to Try access, and a $50 million ARPA-H funding match, with rescheduling to follow upon approval. The FDA followed up in July with final guidance for psychedelic drug development, and Compass Pathways just landed a rolling NDA review with a Commissioner's National Priority Voucher — a sign regulators are finally ready to move on this entire category. Canada has its own momentum building too, with Bill C-286 introduced in June to create a regulated medical psilocybin pathway. Optimi is positioning itself to ride every one of these waves, with an ibogaine finished-dose program now in development and market access already established or expanding across Australia, Canada, the UK, Switzerland, and beyond.
The market this company is chasing is massive: over 100 million people worldwide dealing with treatment-resistant depression and more than 300 million with PTSD, translating into a $232 billion annual PTSD burden in the US alone and a projected $540 billion depression cost by 2030. For a sense of scale on what's possible here, look at J&J's Spravato — a comparable ketamine-based therapy that's scaled to over 7,000 certified clinics and north of $2 billion in annualized sales. Optimi just uplisted to Nasdaq in May 2026, pulled in an oversubscribed $15 million offering, and now holds $9.2 million in cash with insiders owning roughly 17% of the company — real skin in the game. Add in strategic advisors like Lululemon founder Chip Wilson and celebrity trainer Harley Pasternak, and you've got a small-cap manufacturer with commercial revenue, regulatory wind at its back, and a front-row seat to what could be one of the biggest paradigm shifts in mental health treatment in decades.
OPTH fired off back-to-back catalysts earlier this summer, and combined with a fresh Nasdaq listing, a float under 5 million shares, new analyst coverage, and active commercial shipments already underway, this one is sitting at the top of the watchlist this morning. This is a company that has already built the infrastructure, earned the licenses, and is shipping regulated product into live reimbursed markets.
On June 8, the company announced it had secured naturally derived ibogaine from two separate sources, in both hydrochloride and freebase form, with finished product development slated to begin this summer at its GMP facility in British Columbia. That move lands right as a recent U.S. executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review.
Just two days later, on June 10, Optimi announced it had completed its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial, using the same 5mg capsule formulation already prescribed to patients in Australia for treatment-resistant depression. Add to that a sub-5 million share public float, and the combination of a fresh Nasdaq listing, active commercial shipments, new analyst coverage, and tight share availability is exactly why OPTH deserves a closer look right now. This isn't a company still trying to prove it can build compliant infrastructure — Optimi already has licensed facilities, regulated production, and commercial distribution underway.
Optimi Health is doing something entirely different. This company has already built two purpose-built, 10,000-square-foot pharma-grade facilities in Princeton, British Columbia. It already holds its Health Canada Drug Establishment Licence, GMP certification, a Dealer's Licence, and a Class A Precursor Licence. And it is already shipping regulated commercial product to authorized clinics in a live, reimbursed prescription market.
Australia became the world's first country to reschedule psilocybin and MDMA for prescription use, and Optimi is one of the only suppliers in the world actively filling that demand. As of Q1 2026, the company has shipped over 6,000 doses, enough to supply more than 500 patients through Australia's Authorised Prescriber Scheme. Its third commercial psilocybin export of 1,000 capsules just completed this week, earmarked for patients with treatment-resistant depression and reimbursed by payers including Australia's Department of Veterans' Affairs, Medibank, the National Disability Insurance Scheme, and WorkCover.
Now add a fresh Nasdaq uplisting completed alongside a $15 million oversubscribed public offering in May 2026, a public float under 5 million shares, new analyst coverage from Diamond Equity Research with a C$15.00 price target, a first-ever psilocybin export to the United Kingdom, and a brand-new ibogaine supply agreement landing right as a U.S. executive order puts ibogaine on the FDA's accelerated review list. That is a lot of catalysts stacking up at once, and the market is just starting to pay attention.
Why we want to keep a close eye on OPTH
Ibogaine Supply Secured With U.S. Executive Order Tailwind: On June 8, Optimi announced it had secured naturally derived ibogaine from two separate sources in both hydrochloride and freebase form, with finished product development set to begin this summer at its GMP facility in B.C. A recent U.S. executive order specifically named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review.
First-Ever Psilocybin Export to the United Kingdom: On June 10, Optimi completed its first export of naturally derived psilocybin to the UK, supporting a planned Phase 2 clinical trial. The product uses the same 5mg capsule formulation already prescribed to patients in Australia for treatment-resistant depression. This marks Optimi's entry into a second major regulated market.
Third Commercial Psilocybin Shipment to Australia Completed:Optimi just completed its third commercial export of 5mg psilocybin capsules to Australia since launching the product in September 2025, shipping 1,000 capsules for patients with treatment-resistant depression. The product is reimbursed by multiple public and private payers, more than 750 clinicians have been trained to administer the therapy, and no serious adverse events have been reported in over two years of regulated commercial use. These are recurring orders, not one-time deals.
Recent Nasdaq Listing With a Sub-5 Million Share Float: Optimi completed its Nasdaq uplisting in May 2026 alongside a $15 million oversubscribed public offering. With a public float of fewer than 5 million shares, any meaningful shift in demand can have an outsized impact on how this name runs.
Analyst Coverage With Major Upside Target: Diamond Equity Research initiated coverage on May 27, 2026 with a price target of C$15.00 per share. That target represented approximately 89% upside from the C$7.95 level at the time of the report. Analyst Hunter Diamond, CFA, projects long-term gross margins of approximately 75%, driven by the company's largely fixed-cost GMP infrastructure. Management estimates EBITDA breakeven at roughly 1,000 patients per month, with current utilization still well below 1% of installed capacity
A Market Expected to Triple in the Next Decade, And Optimi Is Already Inside It
The global psychedelic therapeutics market is forecast to grow more than 200%, from roughly $3.41 billion in 2026 to approximately $11.03 billion within the next decade. The psychedelic active pharmaceutical ingredient market alone is projected to reach $15 to $17 billion by the early-to-mid 2030s, a 15.2% CAGR. Most of that value flows to upstream, GMP-certified manufacturers. That is exactly where Optimi sits.
Publicly traded sector peers like Compass Pathways (market cap: $1.65B) and AtaiBeckley ($1.58B) are still pre-commercial. Optimi is already generating pharma revenue from two indications in a live, reimbursed market, according to Diamond Equity Research. Its installed capacity supports roughly 1 million MDMA capsules and 1 million psilocybin capsules annually, enough to serve more than 200,000 patients per year under episodic treatment models, with no additional capital spend required. The infrastructure is built. The licenses are live. The orders are coming in.
Optimi Health Corp.: The Regulated GMP Manufacturer Behind Commercial Psychedelic Therapies
Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. Headquartered in Vancouver, British Columbia, the company operates two purpose-built 10,000-square-foot pharma-grade facilities in Princeton, B.C. Its regulatory stack includes a Health Canada Drug Establishment Licence, GMP certification, a Dealer's Licence, and a Class A Precursor Licence, giving it a fully compliant foundation to manufacture and export controlled pharmaceutical substances into regulated markets worldwide.
Optimi's vertically integrated platform covers every step of the supply chain: licensed cultivation, extraction, formulation, encapsulation, quality control, and international distribution. Its commercial revenue is currently anchored in Australia, where the Therapeutic Goods Administration has rescheduled both psilocybin and MDMA to Schedule 8, enabling psychiatrist-led prescribing for PTSD and treatment-resistant depression. MDMA shipments scaled from 160 doses in September 2024 to 1,000-dose repeat orders by February 2026. Psilocybin entered the Australian market in August 2025 and has already been incorporated into Medibank's insurance-backed psychotherapy program. With the UK export now complete and ibogaine development beginning this summer, Optimi is actively expanding its regulated commercial footprint across multiple jurisdictions.
Strengthened Balance Sheet & Analyst-Backed Margin Profile
In May 2026, Optimi completed a $15 million oversubscribed public offering alongside its Nasdaq uplisting, materially strengthening its balance sheet as commercialization scales. The oversubscribed raise signals that institutional demand for OPTH was strong at the moment of listing, a notable sign of confidence heading into accelerating commercial activity.
Diamond Equity Research analyst Hunter Diamond, CFA, initiated coverage on May 27, 2026 with a C$15.00 price target using a DCF model with a WACC of 10.91% and a 2.0% terminal growth rate. The model projects long-term gross margins of approximately 75%, driven by the company's largely fixed-cost GMP infrastructure and protocol-defined dosing. Management has stated that EBITDA breakeven is estimated at approximately 1,000 patients per month.
Already Executing While the Rest of the Sector Is Still Waiting
The psychedelic therapeutics space is filling up with companies making promises. Optimi is delivering. It has built the facilities, earned the licenses, and is generating recurring pharmaceutical revenue from two products in a live, reimbursed prescription market. Its third commercial Australia shipment just closed. Its first UK export just closed. Ibogaine supply has been secured with development starting this summer. And all of this is happening while the broader sector is getting direct regulatory tailwind from a U.S. executive order prioritizing psychedelic therapies for accelerated FDA review.
The market Optimi is serving is expected to grow more than 200% over the next decade. Its installed capacity can serve over 200,000 patients per year without a single dollar of additional manufacturing spend. It is running below 1% utilization today. The margin profile at scale, as modeled by Diamond Equity Research, approaches 75% gross margin. And it is trading as a fresh Nasdaq listing with a float under 5 million shares, in a sector that is receiving more mainstream and regulatory attention than at any point in history.
NEWS
Optimi Health Establishes Discretionary Equity Facility
Aug 14, 2026•
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 29, 2026•
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 29, 2026•
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 16, 2026•
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 16, 2026•
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Jun 10, 2026•
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Jun 10, 2026•
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Jun 8, 2026•
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Jun 8, 2026•
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Jun 2, 2026•
MANAGEMENT
Dane Stevens
Chief Executive Officer & Co-Founder
CEO since October 2024; co-founder since 2020. Nearly two decades in sourcing, manufacturing, and global distribution. Focused on producing GMP-certified MDMA and natural psilocybin for regulated treatment programs.
Robert Martin
Chief Strategy Officer
Seattle-based growth investor for over 20 years, investing at the earliest stages of companies based in the Northwestern US and Canada focused on the betterment of the human condition. Extensive board and advisory board experience, including developing strategic partnerships, making key hires, raising capital, and guiding companies through mergers and acquisitions. As a serial entrepreneur and operator, he and his partner sold two businesses to private equity. He started his career in investment banking upon graduation from George Washington University with an MBA in Finance and Investments.
Jacob Safarik
Chief Financial Officer
Chartered Professional Accountant (CPA). 16+ years in accounting, project finance, business development, and quality assurance. Responsible for financial strategy, capital allocation, and cost management.
Dr. Preston Chase
Chief Science Officer
R&D chemist with 25+ years of experience. BSc from University of Victoria; PhD from University of Calgary. 30+ peer-reviewed publications; multiple awarded and pending patents across catalysis, synthesis, and analytical chemistry.
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF Bullish Media LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
O22 HAS BEEN COMPENSATED A FEE OF TWENTY TWO THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, TD MEDIA, LLC FOR A ONE DaY OPTH PROFILE ON 9/8/26. O22 HAS PREVIOUSLY BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, TD MEDIA, LLC FOR A ONE DAY OPTH PROFILE ON 6/17/26.